G T C Ko
Overview
Explore the profile of G T C Ko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
335
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang Y, Luk A, Chow E, Ko G, Chan M, Ng M, et al.
Diabet Med
. 2017 Sep;
34(12):1701-1709.
PMID: 28945282
Aim: Family history of diabetes is an established risk factor for Type 2 diabetes, but the impact of a family history of young-onset diabetes (onset < 40 years) on future...
2.
Tutino G, Yang W, Li X, Li W, Zhang Y, Guo X, et al.
Diabet Med
. 2016 Jun;
34(3):440-450.
PMID: 27278933
Aims: To test the hypothesis that delivery of integrated care augmented by a web-based disease management programme and nurse coordinator would improve treatment target attainment and health-related behaviour. Methods: The...
3.
Tam C, Wang Y, Luan J, Lee H, Luk A, Tutino G, et al.
Diabet Med
. 2014 Nov;
32(2):220-5.
PMID: 25388749
Aim: To investigate the relationship between birthweight and cardiometabolic traits in two cohorts: one of Chinese adolescents and one of Chinese adults. Methods: Birthweight and clinical data, including anthropometric traits,...
4.
Ko G, Yeung C, Leung W, Chan K, Chung C, Fung L, et al.
Hong Kong Med J
. 2011 Dec;
17 Suppl 6:9-12.
PMID: 22147352
No abstract available.
5.
Kong A, Yamasaki A, Ozaki R, Saito H, Asami T, Ohwada S, et al.
Diabetes Obes Metab
. 2011 Apr;
13(9):806-13.
PMID: 21492364
Aim: To examine the efficacy, safety and tolerability of rivoglitazone, a novel thiazolidinedione (TZD), and explore its effects on glucose and lipid control compared to placebo and pioglitazone in Chinese...
6.
Ma R, Liu K, Lam P, Cheung L, Tam W, Ko G, et al.
J Clin Endocrinol Metab
. 2010 Dec;
96(3):799-807.
PMID: 21190980
Objective: Visceral fat is believed to be important in the pathogenesis of metabolic syndrome and fatty liver. In this study, we examined the relationship between mesenteric fat thickness and other...
7.
Ko G, So W, Tong P, Ma R, Kong A, Ozaki R, et al.
Diabetes Metab
. 2010 Mar;
36(3):192-7.
PMID: 20202879
Aim: This study aimed to confirm the hypothesis that adiponectin levels can enhance the discriminative value of waist circumference (WC) in predicting impaired glycaemic status and clustering of risk factors....
8.
Mok C, Poon W, Lai J, Chiu S, Wong C, Lun S, et al.
Scand J Rheumatol
. 2010 Feb;
39(1):42-9.
PMID: 20132070
Objectives: To study the link between metabolic syndrome (MetS), endothelial injury, and atherosclerosis in patients with systemic lupus erythematosus (SLE). Methods: Consecutive SLE patients without a history of arterial thrombosis...
9.
Tomlinson B, Hu M, Lee V, Lui S, Chu T, Poon E, et al.
Clin Pharmacol Ther
. 2010 Feb;
87(5):558-62.
PMID: 20130569
The ATP-binding cassette G2 (ABCG2) c.421C>A (rs2231142) polymorphism influences the pharmacokinetics of rosuvastatin. We examined whether this polymorphism influences the low-density lipoprotein cholesterol (LDL-C)-lowering efficacy of the drug. In 305...
10.
Chan K, Leung W, Fung Y, Hung H, Tsui P, Chu H, et al.
Ir J Med Sci
. 2009 Feb;
178(2):173-8.
PMID: 19221831
Background: Orlistat is a gastrointestinal lipase inhibitor approved for use in obesity. So far, no evidence has been reported on the use of orlistat in obese patients with coronary artery...